Edition:
United States

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

126.92USD
4:02pm EDT
Change (% chg)

$-0.61 (-0.48%)
Prev Close
$127.53
Open
$127.23
Day's High
$127.67
Day's Low
$126.83
Volume
1,093,155
Avg. Vol
2,027,737
52-wk High
$129.00
52-wk Low
$109.32

Latest Key Developments (Source: Significant Developments)

J&J says expects more than 10 new products to launch or file for regulatory approval by 2021
Wednesday, 17 May 2017 06:44am EDT 

May 17 (Reuters) - Johnson & Johnson :J&J says expects more than 10 new products to launch or file for regulatory approval by 2021.J&J says more than 50 line-extension regulatory filings projected by 2021.  Full Article

Livanova announces Thad Huston as chief financial officer
Tuesday, 16 May 2017 09:00am EDT 

May 16 (Reuters) - Livanova Plc LIVN.O:Livanova announces Thad Huston as chief financial officer.Livanova Plc - Thad Huston will join company as its new chief financial officer effective May 20, 2017.Livanova plc - former CFO, Vivid Sehgal, is coordinating with huston to ensure an orderly transition.Livanova Plc - Huston joins livanova after more than 25 years at Johnson & Johnson, having most recently served as group CFO, medical devices.  Full Article

J&J appoints Jane Griffiths to head Actelion unit
Monday, 15 May 2017 12:07pm EDT 

May 15 (Reuters) - Actelion Ltd :Says Johnson & Johnson has appointed Jane Griffiths as global head of Actelion, to take effect upon closing of transaction.Says Otto Schwarz will retire from his position as chief operating officer upon close of transaction.  Full Article

Depuy Synthes awarded U.S. Department of Defense contract for orthopaedic products
Monday, 15 May 2017 09:00am EDT 

May 15 (Reuters) - Johnson & Johnson :Depuy Synthes awarded U.S. Department of Defense contract for orthopaedic products.Depuy Synthes- under contract, to supply up to $260 million worth of orthopaedic products to defense logistics agency's electronic catalog of medical products.  Full Article

J&J says in March 2017, New Jersey attorney general division of consumer affairs issued subpoena to Janssen Pharmaceuticals
Monday, 8 May 2017 04:56pm EDT 

May 8 (Reuters) - Johnson & Johnson ::J&J says in march 2017, new jersey attorney general division of consumer affairs issued subpoena to janssen pharmaceuticals related to some practices in marketing opioids.J&J says in march, ranking minority member of u.s. Senate committee on homeland security and governmental affairs issued request for information to jpi.J&J - in April, got subpoena from u.s. Attorney for district of Massachusetts for documents relating to pharmaceutical copayment support programs for olysiotm, Simponi, Stelara.J&J says in march 2017, Janssen Biotech Inc received civil investigative demand from U.S. DOJ.  Full Article

Genmab announces new late stage combination study of Daratumumab in multiple myeloma
Friday, 28 Apr 2017 09:26am EDT 

April 28 (Reuters) - Genmab A/S ::Genmab announces new phase III combination study of Daratumumab in multiple myeloma.Study is expected to start in Q2 2017 and is designed to confirm results from MMY1001 study.Prescription drug user fee act date of June 17, 2017 for Daratumumab.Janssen Research with European myeloma network plans to start phase III study of Daratumumab in relapsed and refractory multiple myeloma.  Full Article

J&J increase qtrly dividend by 5 pct to $0.84 per share
Thursday, 27 Apr 2017 10:46am EDT 

April 27 (Reuters) - J&J ::Johnson & johnson announces dividend increase of 5.0 percent.Sets quarterly dividend of $0.84 per share.  Full Article

Actelion says J&J deal on track to close towards end of Q2
Thursday, 27 Apr 2017 01:07am EDT 

April 27 (Reuters) - Actelion Ltd :Publication of the definitive notice of the end result of actelion tender offer.Says publication of definitive notice of end result of actelion tender offer.Says transaction remains on track to close towards end of q2 of 2017.  Full Article

FDA approves Renflexis, biosimilar to Remicade
Friday, 21 Apr 2017 03:54pm EDT 

April 21 (Reuters) - FDA::FDA approves Renflexis, biosimilar to Remicade.  Full Article

Johnson & Johnson sees Actelion adding 35-50 cents to 2018 EPS
Tuesday, 18 Apr 2017 09:36am EDT 

April 18 (Reuters) - Johnson & Johnson :Johnson & johnson sees Actelion acquisition adding 35-50 cents to EPS in 2018.J&J CFO says continues to evaluate options for diabetes business, including partnerships, divestitures.  Full Article

More From Around the Web

J&J's Ethicon hit with $2.16 million verdict in vaginal-mesh case

A state court jury in Philadelphia on Friday ordered Johnson & Johnson to pay $2.16 million to a Pennsylvania woman who claimed she suffered injuries due to pelvic mesh devices manufactured by the company's Ethicon unit.